Eos Focused Equity Management adds Baxter International Inc (BAX) to its portfolio

Baxter International Inc (BAX) : Eos Focused Equity Management added new position in Baxter International Inc during the most recent quarter end. The investment management firm now holds 62,136 shares of Baxter International Inc which is valued at $3,046,528 , the company said in a statement filed on Aug 9, 2016 with the SEC.Baxter International Inc makes up approximately 3.09% of Eos Focused Equity Management’s portfolio.

Other Hedge Funds, Including , Aspiriant added BAX to its portfolio by purchasing 12,965 company shares during the most recent quarter which is valued at $635,674. Baxter International Inc makes up approx 0.05% of Aspiriant’s portfolio.Anchor Capital Advisors reduced its stake in BAX by selling 59,610 shares or 3.82% in the most recent quarter. The Hedge Fund company now holds 1,499,351 shares of BAX which is valued at $72,148,770. Baxter International Inc makes up approx 1.85% of Anchor Capital Advisors’s portfolio.Sigma Planning Corp reduced its stake in BAX by selling 500 shares or 4.63% in the most recent quarter. The Hedge Fund company now holds 10,295 shares of BAX which is valued at $476,864. Baxter International Inc makes up approx 0.06% of Sigma Planning Corp’s portfolio.Murphy Pohlad Asset Management boosted its stake in BAX in the latest quarter, The investment management firm added 5,035 additional shares and now holds a total of 61,291 shares of Baxter International Inc which is valued at $2,869,645. Baxter International Inc makes up approx 2.08% of Murphy Pohlad Asset Management’s portfolio. Banced Corp added BAX to its portfolio by purchasing 8,225 company shares during the most recent quarter which is valued at $385,095. Baxter International Inc makes up approx 0.67% of Banced Corp’s portfolio.

Baxter International Inc closed down -0.26 points or -0.54% at $47.98 with 37,69,052 shares getting traded on Wednesday. Post opening the session at $48.3, the shares hit an intraday low of $47.55 and an intraday high of $48.35 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Baxter International Inc reported $0.46 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Jul 26, 2016. Analyst had a consensus of $0.40. The company had revenue of $2585.00 million for the quarter, compared to analysts expectations of $2516.16 million. The company’s revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.00 EPS.

Investors should note that on Jul 19, 2016, Baxter International Inc announced a cash dividend of $0.1300. The company’s management has announced Aug 31, 2016 as the ex-dividend date and fixed the record date on Sep 2, 2016. The payable date has been fixed on Oct 3, 2016.

Many Wall Street Analysts have commented on Baxter International Inc. Company shares were Reiterated by RBC Capital Mkts on Jul 27, 2016 to “Sector Perform”, Firm has raised the Price Target to $ 50 from a previous price target of $47 .Baxter International Inc was Resumed by JP Morgan to “Neutral” on Jun 6, 2016.

Baxter International Inc. (Baxter) is a diversified healthcare company. The Company operates in two segments: BioScience segment which include three commercial franchises: Hemophilia BioTherapeutics and BioSurgery and Medical Products segment which include four commercial franchises: Fluid Systems Renal Specialty Pharmaceuticals and BioPharma Solutions. Its BioScience processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies alpha-1 antitrypsin deficiency burns and shock and other chronic and acute blood-related conditions and biosurgery products. Its Medical Products manufactures intravenous (IV) solutions and administration sets premixed drugs and drug-reconstitution systems pre-filled vials and syringes for injectable drugs IV nutrition products infusion pumps and inhalation anesthetics. Its products are used in hospitals kidney dialysis centers and nursing homes among others.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Baxter International Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Baxter International Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.